T Thomas1, D Gilbert, P V Kaye, I Penman, G P Aithal, Krish Ragunath. 1. Nottingham Digestive Diseases Centre and Biomedical Research Unit, Nottingham University Hospitals NHS Trust, Queens Medical Centre Campus, Nottingham NG7 2UH, UK.
Abstract
BACKGROUND: Endoscopic ultrasound (EUS) is useful for detecting depth of invasion and nodal involvement in patients with early Barrett's neoplasia (EBN), precluding endoscopic management. This study aimed to determine whether the lesion morphology of the EBN shown on high-resolution endoscopy predicts EUS and histologic tumor stage. METHODS: Retrospective series from two tertiary referral centers were studied. Patients with EBN referred for EUS evaluation before treatment were identified, and data were collected from endoscopies, a database, and case notes. All patients had high-resolution endoscopy followed by radial EUS. RESULTS: This study included 50 patients (22 men) with a median age of 69 years (interquartile range, 60-79 years). Visible lesions in the Barrett's segment were described as Paris types 0-1 (n = 9), 0-IIb (n = 12), 0-IIa (n = 12), 0-IIa + IIc (n = 6), and 0-IIc (n = 5). Of the 50 patients, 46 (92%) had either EMR (n = 17), esophagectomy (n = 23), or both (n = 6). All 12 patients (100%) with Paris 0-IIb lesions had T0/T1 m staging on EUS confirmed with resection histology. The sensitivity for EUS T-staging for Paris classification was 71.4% for type 0-I, 100% for type 0-IIb, 83% for type 0-IIa, 66.7% for type 0-IIa + IIc, and 66.7% for type IIc. Overall, 8 (17%) of the 46 patients were understaged and 2 (4%) were overstaged. For detecting submucosal invasion, EUS had a sensitivity of 66%, a specificity of 93%, a negative predictive value of 85%, and a diagnostic accuracy of 84.4%. CONCLUSION: Submucosal invasion is detected by EUS for 26% of patients with EBN. The value of EUS staging before resection for type 0-IIb early Barrett's cancer (flat lesions) is limited because 100% of these lesions are limited to the mucosa. For the management algorithm in this selected cohort, the use of EUS should be reconsidered.
BACKGROUND: Endoscopic ultrasound (EUS) is useful for detecting depth of invasion and nodal involvement in patients with early Barrett's neoplasia (EBN), precluding endoscopic management. This study aimed to determine whether the lesion morphology of the EBN shown on high-resolution endoscopy predicts EUS and histologic tumor stage. METHODS: Retrospective series from two tertiary referral centers were studied. Patients with EBN referred for EUS evaluation before treatment were identified, and data were collected from endoscopies, a database, and case notes. All patients had high-resolution endoscopy followed by radial EUS. RESULTS: This study included 50 patients (22 men) with a median age of 69 years (interquartile range, 60-79 years). Visible lesions in the Barrett's segment were described as Paris types 0-1 (n = 9), 0-IIb (n = 12), 0-IIa (n = 12), 0-IIa + IIc (n = 6), and 0-IIc (n = 5). Of the 50 patients, 46 (92%) had either EMR (n = 17), esophagectomy (n = 23), or both (n = 6). All 12 patients (100%) with Paris 0-IIb lesions had T0/T1 m staging on EUS confirmed with resection histology. The sensitivity for EUS T-staging for Paris classification was 71.4% for type 0-I, 100% for type 0-IIb, 83% for type 0-IIa, 66.7% for type 0-IIa + IIc, and 66.7% for type IIc. Overall, 8 (17%) of the 46 patients were understaged and 2 (4%) were overstaged. For detecting submucosal invasion, EUS had a sensitivity of 66%, a specificity of 93%, a negative predictive value of 85%, and a diagnostic accuracy of 84.4%. CONCLUSION: Submucosal invasion is detected by EUS for 26% of patients with EBN. The value of EUS staging before resection for type 0-IIb early Barrett's cancer (flat lesions) is limited because 100% of these lesions are limited to the mucosa. For the management algorithm in this selected cohort, the use of EUS should be reconsidered.
Authors: Irving Waxman; Gottumukkala S Raju; Jonathan Critchlow; Donald A Antonioli; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2006-06-16 Impact factor: 10.864
Authors: Christianne J Buskens; Marinke Westerterp; Sjoerd M Lagarde; Jacques J G H M Bergman; Fiebo J W ten Kate; J Jan B van Lanschot Journal: Gastrointest Endosc Date: 2004-11 Impact factor: 9.427
Authors: Femke P Peters; Mohammed A Kara; Wilda D Rosmolen; Fiebo J W ten Kate; Kausilia K Krishnadath; J Jan B van Lanschot; Paul Fockens; Jacques J G H M Bergman Journal: Am J Gastroenterol Date: 2006-07 Impact factor: 10.864
Authors: Sabrina Rampado; Paolo Bocus; Giorgio Battaglia; Alberto Ruol; Giuseppe Portale; Ermanno Ancona Journal: Ann Thorac Surg Date: 2008-01 Impact factor: 4.330
Authors: Hendrik Manner; Andrea May; Oliver Pech; Liebwin Gossner; Thomas Rabenstein; Erwin Günter; Michael Vieth; Manfred Stolte; Christian Ell Journal: Am J Gastroenterol Date: 2008-09-10 Impact factor: 10.864
Authors: O Pech; L Gossner; H Manner; A May; T Rabenstein; A Behrens; M Berres; J Huijsmans; M Vieth; M Stolte; C Ell Journal: Endoscopy Date: 2007-07 Impact factor: 10.093
Authors: W J Bulsiewicz; E S Dellon; A J Rogers; S Pasricha; R D Madanick; I S Grimm; N J Shaheen Journal: Dis Esophagus Date: 2012-09-27 Impact factor: 3.429
Authors: Alejandro Nieponice; Adolfo E Badaloni; Blair A Jobe; Toshitaka Hoppo; Carlos Pellegrini; Vic Velanovich; Gary W Falk; Kevin Reavis; Lee Swanstrom; Virender K Sharma; Fabio Nachman; Franco F Ciotola; Luis E Caro; Cecilio Cerisoli; Demetrio Cavadas; Luis Durand Figueroa; Daniel Pirchi; Michael Gibson; Santiago Elizalde; Henry Cohen Journal: World J Surg Date: 2014-01 Impact factor: 3.352